A high-throughput screening platform for identifying selective cancer drug targets and therapeutics

Background

The field of cancer therapeutics has long focused on disrupting cell division, as uncontrolled proliferation is a hallmark of cancer. Central to this process is the mitotic spindle, a dynamic structure composed of microtubules that segregate chromosomes during mitosis. Traditional anti-cancer drugs, such as taxanes and vinca alkaloids, target microtubules to inhibit cell division. However, because microtubules are essential for many cellular functions beyond mitosis—including intracellular transport and maintenance of cell shape—these drugs often cause significant toxicity in healthy, non-cancerous cells. This off-target toxicity leads to severe side effects, limiting the therapeutic window and efficacy of current treatments. As a result, there is a critical need for more selective approaches that can specifically target cancer cell division without harming normal tissues.

Current approaches to cancer drug discovery often rely on whole-cell assays that screen for compounds disrupting the mitotic spindle, but these methods lack specificity. The mitotic spindle is composed of numerous proteins involved in a variety of cellular processes, making it difficult to identify drugs that selectively target cancer-specific mechanisms. Furthermore, whole-cell screens are limited by the complexity of cellular membranes and the presence of multiple, redundant pathways, which can obscure the identification of truly selective drug candidates. Broadly acting microtubule-targeting agents, while effective at halting cell division, do not discriminate between healthy and cancerous cells, resulting in widespread cytotoxicity. This lack of specificity underscores the need for innovative screening methods that can isolate and interrogate individual pathways critical to cancer cell proliferation, thereby enabling the discovery of next-generation therapeutics with improved safety profiles.

Technology

This technology is a high-throughput screening platform designed to identify novel cancer drug targets and therapeutics by focusing on the branching microtubule nucleation pathway, a critical process in mitotic spindle assembly during cell division. The platform leverages Xenopus egg extract arrested in meiosis II, which, when combined with RanGTP, induces branching microtubule nucleation—a process heavily reliant on the protein TPX2, known to be overexpressed in cancer cells. Candidate molecules are introduced into multi-well glass bottom dishes or flow cells, and after a controlled incubation, the reactions are fixed and imaged to detect phenotypic changes. The system is optimized for automation, utilizing robotic mechanisms for pipetting, fixation, and imaging, alongside dedicated software for rapid, quantitative analysis of results. This approach enables the efficient screening of large compound libraries to pinpoint molecules that specifically disrupt cancer-relevant microtubule dynamics.

What sets this technology apart is its specificity and potential to reduce toxicity compared to traditional microtubule-targeting cancer drugs. By isolating and targeting the branching microtubule nucleation pathway—rather than broadly affecting all microtubule functions—the platform minimizes off-target effects on healthy cells, addressing a major limitation of existing therapies like taxol. The use of a cell-free extract system circumvents the complexities and barriers associated with whole-cell assays, allowing for direct access to the molecular machinery of spindle assembly. Furthermore, the identification of a new class of spindle assembly proteins as drug targets opens avenues for the development of therapeutics that are both highly selective and effective. The platform’s automation and scalability make it a powerful tool for accelerating the discovery of next-generation cancer treatments with improved safety profiles.

Benefits

• Enables identification of novel cancer drug targets by focusing on a specific, cancer-relevant pathway (branching microtubule nucleation) essential for mitotic spindle assembly.
• Reduces off-target effects and toxicity to healthy cells compared to existing broad microtubule-targeting drugs.
• Uses a cell-free Xenopus egg extract system, avoiding limitations of whole-cell assays and allowing direct access to intracellular pathways.
• Supports high-throughput, automated screening with robotic pipetting, fixation, imaging, and dedicated analysis software for efficient drug discovery.
• Facilitates discovery of therapeutics that selectively inhibit cancer cell division by targeting the overexpressed protein TPX2.
• Offers potential applicability to other diseases involving cell proliferation, cell shape, or microtubule dynamics beyond cancer.
• Enables early-stage validation of drug candidates in vitro, with downstream testing in human cells and animal models to assess efficacy and safety.

Applications

• High-throughput cancer drug discovery
• Automated screening for TPX2 inhibitors
• Selective anti-mitotic drug development
• Phenotypic screening for oncology therapeutics

Additional info

This screening method identifies novel cancer drug targets by assaying branching microtubule nucleation. It utilizes Xenopus egg extract and RanGTP in multi-well systems to induce and visualize specific cellular pathway changes. Automated imaging and analysis determine the activity of tested molecules, enabling high-specificity therapeutic discovery with reduced off-target effects.